Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 76

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 76
---
isclosure agreements with Aadi and received virtual data room access. Over the next few weeks, such parties conducted commercial and scientific due diligence on
the FYARRO commercial business.

On September 4, 2024, representatives of Aadi and Bidder C met via videoconference to discuss the FYARRO commercial
business and Bidder C’s initial due diligence questions.

On that same day, representatives of Aadi and Bidder E met via videoconference to discuss
the FYARRO commercial business and Bidder E’s initial due diligence questions.

On September 5, 2024, representatives of Aadi and Bidder G met
via videoconference to discuss the FYARRO commercial business and Bidder G’s initial due diligence questions.

On September 9, 2024, Bidder A
submitted a non-binding indication of interest to acquire Aadi, in a transaction structured as a sale of the whole company, at a valuation of approximately $2.20 per share on a fully diluted basis, an implied
premium of 20% over Aadi’s closing price on September 6, 2024 ($1.83).

On September 11, 2024, Bidder B submitted a non-binding indication of interest to acquire the FYARRO assets for cash consideration at closing of $80 million, on a cash-free, debt-free basis (the “Bidder B September 11 Proposal”). Bidder B
planned to finance the transaction with a combination of cash on hand, new equity from Bidder B’s private equity sponsor, and debt from existing lenders with whom Bidder B and its private equity sponsor have longstanding relationships.

On that same day, Bidder C submitted a non-binding indication of interest to exclusively license the FYARRO assets for
the PEComa indication for cash consideration at closing of $45 million.

On September 12, 2024, Bidder D submitted a non-binding indication of interest to exclusively license the FYARRO assets for: (i) a one-time upfront cash payment of $35.0 million; (ii) two potential one-time commercial milestone cash payments of $5.0 million and $10.0 million; and (iii) certain ongoing cash royalty payments.

On that same day, Bidder E communicated via email to representatives of Leerink Partners that it was interested in acquiring the FYARRO assets for cash
consideration at closing of $50 million.

On September 13, 2024, Bidder F submitted a non-binding